GLP T was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.
GLP T was originally developed to treat Type-2 diabetes but has since become a leading anti-obesity medication. It is a dual agonist of the GLP-1 and GIP receptors — meaning it activates two distinct hormonal pathways to reduce appetite, improve metabolic rate, and support sustained weight loss.